Gerds, the deputy director for Clinical Research at Cleveland Clinic Taussig Cancer Institute, discussed how monitoring for mutations in the bone marrow can help doctors find who is at an increased ...

Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute ... of platelet counts in patients with essential thrombocythemia. “What we need in essential thrombocythemia ...

as treatment for essential thrombocythemia. “This, as a cytoreductive agent, is a very active compound,” said Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer ...

A subset of patients with myeloproliferative neoplasms (MPNs) -- clonal disorders of hematopoietic stem cells that include ...

This is called primary thrombocythemia. If it's caused by an underlying disorder that triggers the stem cells in your bone marrow to make more platelets, it's called secondary thrombocytosis.

It has been shown to inhibit megakaryocytic proliferation in vitro in cells obtained from patients with essential thrombocythemia. In this phase 2 study, we investigated whether imetelstat could ...

This panel was moderated by Ryan McDonald and featured Dr. Aaron Gerds, from Cleveland Clinic, and Dr. Douglas Tremblay, from Mount Sinai, who answered questions about essential thrombocythemia (ET).